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Abstract
Development of bone metastases is dependent on the cancer cell-bone cell interactions in the bone microenvironment.
Transforming growth factor b (TGF-b) is released from bone during osteoclastic bone resorption and induces production of
osteolytic factors, such as interleukin 11 (IL-11), in breast cancer cells. IL-11 in turn increases osteolysis by stimulating
osteoclast function, launching a vicious cycle of cancer growth and bone destruction. We aimed to identify and functionally
characterize microRNAs (miRNAs) that mediate the bone metastatic process, focusing on miRNAs that regulate the TGF-
b induction of IL-11. First, we profiled the expression of 455 miRNAs in a highly bone metastatic MDA-MB-231(SA) variant as
compared to the parental MDA-MB-231 breast cancer cell line and found 16 miRNAs (3.5%) having a .3-fold expression
difference between the two cell types. We then applied a cell-based overexpression screen with Pre-miRNA constructs to
functionally identify miRNAs regulating TGF-b-induced IL-11 production. This analysis pinpointed miR-204, miR-211, and
miR-379 as such key regulators. These miRNAs were shown to directly target IL11 by binding to its 39 UTR. MiR-379 also
inhibited Smad2/3/4-mediated transcriptional activity. Gene expression analysis of miR-204 and miR-379-transfected cells
indicated that these miRNAs downregulated the expression of several genes involved in TGF-b signaling, including
prostaglandin-endoperoxide synthase 2 (PTGS2). In addition, there was a significant correlation between the genes
downregulated by miR-379 and a set of genes upregulated in basal subtype of breast cancer. Taken together, the functional
evidence and clinical correlations imply novel mechanistic links between miRNAs and the key steps in the bone metastatic
process in breast cancer, with potential clinical relevance.
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Introduction
Metastasis to bone is the most frequent cause of breast cancer
morbidity and mortality. Currently available therapies are able to
alleviate painful symptoms but bone metastatic cancer remains
incurable. This is due to limited understanding of the integral
molecular and cellular determinants of the bone metastatic
process. Gene expression profiling of clinical tumor samples and
experimental in vivo studies have revealed sets of genes whose
expression in tumor cells correlates with their metastatic potential
[1]. Many of these genes have been shown to play an important
role in different phases of metastatic progression, but a therapeu-
tically applicable common regulatory mechanism governing
a multitude of these gene expression changes in tumor cells is
yet to be discovered. MicroRNAs (miRNAs) are attractive
candidates as multifunctional regulators of metastatic progression
because one miRNA can regulate an entire set of genes. There is
an increasing amount of evidence for under- and overexpression of
several miRNAs in cancer, as compared to the normal tissue, and
for the impact of miRNAs in epithelial-to-mesenchymal transition
(EMT) [2] and metastatic progression (reviewed in [3]). The
specific role of miRNAs in the bone metastatic process of breast
cancer has not been extensively studied, but available early results
suggest miRNAs as potential key regulators [4–6].
Transforming growth factor b (TGF-b) is one of the key tumor-
promoting growth factors in advanced cancers. It induces EMT
and has a key role in the bone metastatic process, in the vicious
cycle between bone and breast cancer cells. TGF-b regulates cell
type-specific transcriptional responses via canonical Smad and
non-Smad signaling pathways (reviewed in [7]). In the bone
microenvironment, TGF-b is released from bone during bone
resorption and it stimulates breast cancer cells to produce
osteolytic factors, such as interleukin 11 (IL-11), that mediate
osteolysis by stimulating osteoclast formation and bone resorption
activity [8–10]. High expression of IL-11 correlates with high
histological grade and poor survival in breast cancer [11]. Total
systemic blockade of TGF-b signaling pathway by neutralizing
antibodies against TGF-b or small molecule inhibitors against the
type I TGF-b receptor kinase activity prevents bone metastases in
preclinical models [12,13] but may cause off-target effects because
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suppressing effects during early stages of breast cancer.
The aim of this study was to elucidate the role of miRNAs in the
bone metastatic process of breast cancer and specifically, to
identify miRNAs that regulate TGF-b-induced IL-11 expression.
We first used array-based miRNA expression profiling of highly
bone metastatic variant MDA-MB-231(SA) and parental MDA-
MB-231 cells and functional cell-based miRNA overexpression
screening to identify miRNAs with a potential role in the TGF-b-
induced IL-11 production.
Results
MiRNA Expression Profiling of Highly Bone Metastatic
MDA-MB-231(SA) and Parental MDA-MB-231 Cells
We have previously demonstrated that despite the remarkably
enhanced bone metastatic capability of the MDA-MB-231(SA)
variant as compared to the parental MDA-MB-231 cell line in
a mouse model of bone metastasis, its genome-wide gene
expression and copy number profiles are relatively similar to
those of the parental cells [14]. To complement these analyses, we
measured the expression of 455 miRNAs in the highly bone
metastatic MDA-MB-231(SA) variant and parental MDA-MB-231
cells. We found that 16 (3.5%) of the miRNAs were differentially
expressed (.3-fold) between the cell types. Of these, five miRNAs
(miR-200b, miR-200a, miR-210, miR-429, and miR-152) were
downregulated and eleven (miR-504, miR-196a, miR-142-3p,
miR-142-5p, miR-105, miR-517c, miR-363, miR-135b, miR-521,
miR-145, and miR-582) upregulated in the highly bone metastatic
as compared to the parental MDA-MB-231 cells (Table S1).
Identification of miRNAs that Regulate IL-11 Production
One of the cell biological properties of the highly metastatic
MDA-MB-231(SA) cells is that their TGF-b-induced IL-11
expression is highly elevated as compared to the parental MDA-
MB-231 cells [15]. We hypothesized that one or several miRNAs
might be responsible for the increased IL-11 production. In order
to test this, we performed overexpression screens with miRNA
precursors in MDA-MB-231(SA) cells and measured the IL-11
secretion levels in the absence and presence of added TGF-b in the
medium. We chose to screen for miRNAs that were down-
regulated in the MDA-MB-231(SA) cells and the miRNAs that
were predicted to target IL11 according to the miRanda, PicTar,
or TargetScan prediction algorithm. This combined selection
resulted in 55 miRNAs. Analysis of the replicate screens revealed
that the miRNAs .3-fold downregulated in the MDA-MB-
231(SA) cells did not have a clear inhibitory effect on IL-11
secretion. Instead, miR-204, -211, and -379 were the most potent
inhibitors of IL-11 secretion (Figure 1) and were selected for
further studies. MiR-204, -211, and -379 decreased both IL-11
secretion (Figure 2A) and IL11 mRNA levels (Figure 2B).
Furthermore, inhibition of miR-204 and miR-211 by specific
Anti-miR inhibitors increased IL-11 secretion in the parental
MDA-MB-231 cells (Figure 2C).
MiR-204, -211, and -379 Bind to the IL11 39 UTR
We wanted to see whether the inhibitory effect of miR-204, -
211, and -379 on IL-11 expression was due to direct targeting, i.e.
binding of miR-204, -211, and -379 to IL11 mRNA. First, we used
six different miRNA target prediction algorithms (miRanda,
PicTar, TargetScan, DIANA-microT, miRDB, and PITA) to
investigate in detail the potential of miR-204, -211, and -379
binding to the IL11 39 untranslated region (UTR). Four
algorithms, miRanda, DIANA-microT, miRDB, and PITA all
predicted two binding sites in the IL11 39 UTR for miR-204 and -
211 (Table S2). These two miRNAs share the same seed sequence
and only differ in two nucleotides on positions 17 and 18.
MiRanda, PicTar, TargetScan, DIANA-microT, or miRDB did
not predict binding of miR-379 to the IL11 39 UTR but according
to the PITA tool, there are seventeen 6-mer seed sites and one 7-
mer seed site for miR-379 in the IL11 39 UTR (Table S2).
Subsequently, we performed luciferase reporter assays to de-
termine whether miR-204, -211, or -379 inhibit the expression of
the luciferase reporter gene by binding to the IL11 39 UTR
sequence. Binding to the 39 UTR was assayed in two parts: base
pairs 1–450 and 451–1,618. A luciferase reporter construct
containing one of the two fragments was transfected into MDA-
MB-231(SA) cells together with an miRNA precursor and a Renilla
luciferase control plasmid. When compared to the negative control
Pre-miR, miR-204 inhibited the reporter activity of the construct
containing the 451–1,618 end of the UTR. MiR-211 and -379
inhibited the reporter activity of both of the constructs, indicating
that they bind to at least two sites in the IL11 39 UTR (Figure 3).
Additional Gene Expression Changes Induced by miR-204
and miR-379 in MDA-MB-231(SA) Cells
Because of the multi-gene regulatory capacity of miRNAs, it is
likely that miR-204, -211, and -379 downregulate the expression
of IL11 through additional mechanisms beyond direct targeting. In
order to gain a broader understanding of the regulatory functions
of these miRNAs, we performed genome-wide gene expression
analysis of MDA-MB-231(SA) cells that had been transfected with
miR-204 or -379 precursors. MiR-211 was not included in the
analysis because it shares the same seed sequence with miR-204.
Because we wanted to analyze the primary effects of these
miRNAs and not the secondary effects caused by IL11 silencing,
the samples for gene expression analysis were collected already 24
hours after transfection. Furthermore, cells transfected with IL11
siRNA were also profiled. Using 1.5-fold difference to the negative
control siRNA or Pre-miR as a cut-off, the only common gene
between the IL11 siRNA, Pre-miR-204, and Pre-miR-379-treated
cells was IL11. In addition, cyclin-dependent kinase 6 (CDK6) was
downregulated by both miR-379 and IL11 siRNA. There was an
overlap of 15 genes between the genes over 1.5-fold differentially
expressed in response to miR-204 and -379. In addition to IL11,
prostaglandin-endoperoxide synthase 2 (PTGS2, also known as
COX-2), ribosomal protein L10a (RPL10A), ribosomal protein
L21 (RPL21), C4orf26, LOC642989, and LOC654194 were
downregulated over 1.5-fold by both miR-204 and -379. In-
terestingly, miR-204 downregulated the expression of interleukin
1 beta (IL1B), interleukin 6 (IL6), and osteopontin (SPP1).
Furthermore, a number of genes that have been reported as
direct targets of miR-204/211 [16–20], AP1S2, SERP1, M6PR,
RAB22A, BIRC2, BCL2L2, and TGFBR2, were downregulated
over 1.5-fold by miR-204. Of note, miR-379 downregulated the
expression of plasminogen activator inhibitor type 1 (SERPINE1,
also known as PAI-1), which is a TGF-b-responsive gene [21], as
well as endothelin 1 (EDN1, also known as ET-1) and bone
morphogenetic protein 2 (BMP2) (Figure 4, Tables S3 and S4).
The genes that were over 1.5-fold downregulated in response to
miR-204 or -379 versus negative control Pre-miR were compared
against the gene signatures in the Molecular Signatures Database
(MSigDB). Among the MSigDB microRNA target sets, miR-204
showed a significant overlap exclusively with the MSigDB set of
genes containing a 39 UTR binding motif for miR-204
(p=8.13610
24) (Table S5). Respectively, the genes downregu-
lated in response to miR-379 correlated significantly with the
MSigDB miR-379 gene set only (p=6.13610
24). In addition,
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PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37361Figure 1. Effects of 55 miRNA precursors and a negative control on IL-11 secretion in MDA-MB-231(SA) cells. Cells were transfected
with miRNA precursors in 96-well plates. Medium was changed 24 hours after transfection (+/2 TGF-b), and IL-11 concentration in the conditioned
medium was measured 24 hours later. IL-11 concentration was normalized to the number of viable cells in the well. The scale of reduction (blue) or
increase (red) in IL-11 concentration in the conditioned medium is represented in the color graph in the upper right hand corner of the figure.
doi:10.1371/journal.pone.0037361.g001
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regulated by miR-379 and a set of genes upregulated in basal
subtype of breast cancer samples (p=2.82610
25) and a set of
genes downregulated in luminal-like breast cancer cell lines
compared to the mesenchymal-like ones (p=1.06610
27) (Table
S6).
Figure 2. The effects of miR-204, -211 and -379 on IL-11 secretion and IL11 mRNA expression. A. IL-11 concentration in the conditioned
medium of MDA-MB-231(SA) cells overexpressing miR-204, -211, or -379 (n=3). B. IL11 mRNA expression changes in MDA-MB-231(SA) cells
overexpressing miR-204, -211, or -379 (n=3). C. IL-11 concentration in the conditioned medium of parental MDA-MB-231 cells whose miR-204, -211,
or -379 expression was inhibited by specific Anti-miR inhibitors (n=3). * p,0.05, ** p,0.01, *** p,0.001, as compared to the negative control Pre-
miR or Anti-miR.
doi:10.1371/journal.pone.0037361.g002
Figure 3. IL11 39 UTR luciferase assay. Luciferase reporter constructs, each containing one fragment of the IL11 39 UTR, were co-transfected with
a Renilla luciferase construct and the miRNA precursors into MDA-MB-231(SA) cells (n=5), and luciferase activity was measured 28 hours later. *
p,0.05, ** p,0.01, *** p,0.001, as compared to the negative control Pre-miR.
doi:10.1371/journal.pone.0037361.g003
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Given the above results on the inhibitory effects of miR-204 and
-379 on the expression of not only IL11 but also other genes that
have been shown to be regulated by TGF-b, such as PTGS2 (miR-
204 and -379) and SERPINE1 (miR-379), we next studied whether
miR-204, -211, or -379 affected Smad signaling. Binding of TGF-
b to the TGF-b type II receptor induces the TGF-b receptor type I
kinase activity and leads to the phosphorylation of Smad2 and
Smad3. Phosphorylated Smads form heteromeric complexes with
Smad4, and the Smad complex translocates into the nucleus and
interacts with transcriptional activators and repressors to regulate
target gene expression. We measured the effects of miR-204, -211,
and -379 on Smad2/3/4-mediated transcriptional activity using
a luciferase reporter construct containing a functional Smad
binding site. Surprisingly, miR-211 (as well as miR-204 but not
significantly) increased the TGF-b-induced luciferase signal,
indicating an increase in Smad binding to its response element.
MiR-379 in turn inhibited the Smad-mediated transcriptional
activity as shown by a marked reduction in the luciferase signal
(Figure 5). We also measured the effects of Anti-miR-204 and -379
on Smad signaling in the MDA-MB-231(SA) as well as in the
parental MDA-MB-231 cells. Inhibition of miR-204 led to
a decrease in the TGF-b-induced luciferase signal in both cell
types. Anti-miR-379 increased the signal in the MDA-MB-
231(SA) cells but did not show any significant effect in the
parental MDA-MB-231 cells (Figure S1).
Discussion
In our comparison of the miRNA expression profiles between
the highly bone metastatic MDA-MB-231(SA) variant and the
parental MDA-MB-231 cell line, we found 16 miRNAs that were
differentially expressed by more than 3-fold. The miR-200 family
was strongly represented: three of the five family members, miR-
200b, -200a, and -429, were among the four most downregulated
miRNAs in the highly metastatic MDA-MB-231(SA) cells. The
role of these miRNAs in EMT has previously been reported by
Gregory et al. [2]. Interestingly, miR-210, whose high expression
has previously been associated with increased likelihood of distant
metastasis [22] and poor clinical outcome [23] in breast cancer,
was 6.5-fold downregulated in the MDA-MB-231(SA) cells.
Because of the highly increased IL-11 production in MDA-MB-
231(SA) cells in response to TGF-b, we chose to screen for
miRNAs whose overexpression inhibits IL-11 production in
MDA-MB-231(SA) cells. We identified miR-204, -211, and -379
as the strongest modulators of IL-11 production. We demonstrated
that miR-204, -211, and -379 reduced not only IL-11 secretion but
IL11 mRNA levels as well. Furthermore, our results from the
luciferase reporter assays indicated that miR-204 and -211 bind to
the IL11 39 UTR which is in concordance with the predictions of
several different bioinformatic algorithms that predicted IL11 as
a direct target for miR-204 and -211. To our knowledge, miR-211
or -379 have not been previously linked to IL-11 production or
breast cancer metastasis. In regard to miR-204, our finding is in
line with a previous report showing reduced expression of IL-11 at
protein level in miR-204-transfected human trabecular meshwork
cells [19].
According to miRNA target prediction tools, binding of miR-
379 to the IL11 39 UTR seemed unlikely. However, our laboratory
experiments showed that also miR-379 binds to the IL11 39 UTR.
This inconsistency might be due to the fact that common
Figure 4. Genes over 1.5-fold downregulated in response to miR-204 and/or -379 versus negative control Pre-miR. RNA samples for
genome-wide gene expression analysis were collected 24 hours after MDA-MB-231(SA) cells had been transfected with miRNA precursors. The
predicted targets of miR-204 are typed in red and the predicted targets of miR-379 in blue. Expression fold changes, gene names, and more detailed
information about the target predictions are listed in the Tables S3 and S4.
doi:10.1371/journal.pone.0037361.g004
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there is only one 7-base pair seed match and no 8-base pair
matches for miR-379 in the IL11 39 UTR. It was recently reported
that up to 67% of functional miRNA binding sites are based on 6-
mer seeds [24]. Recent high-throughput analyses of miRNA-
mRNA pairing also suggest that 25–45% of binding sites lack
a perfect seed match [25,26], and there is an increasing list of
validated binding sites lacking a canonical seed [27–30]. Together
with these previously published evidence, our finding on the miR-
379 binding to the IL11 39 UTR indicates that bioinformatic
prediction of miRNA targeting is lacking sensitivity, reflecting our
insufficient knowledge of miRNA binding patterns.
Inhibition of miR-204 or -211 in the parental MDA-MB-231
cells led to increased IL-11 secretion, suggesting that these
miRNAs could be one underlying reason for the low levels of
secreted IL-11 in these cells as compared to the highly metastatic
variant. Inhibition of miR-379, in turn, did not significantly affect
IL-11 secretion in the parental cells. This indicates that apart from
direct targeting of IL11 mRNA, miR-379 and miR-204/2211
work through different mechanisms and that there is a regulatory
mechanism keeping the IL-11 levels down in the MDA-MB-231
cells which is not significantly affected by the inhibition of miR-
379. In addition, our results from the gene expression profiling of
miR-204 and -379-transfected MDA-MB-231(SA) cells showed
that the overlap between the gene expression changes caused by
these miRNAs was low, suggesting that except for downregulating
IL11 expression, miR-204 and -379 largely engage in distinct
regulatory pathways. However, both miR-204 and -379 down-
regulated the expression of PTGS2. Based on previous publica-
tions, TGF-b stimulates PTGS2 expression in breast cancer cells
[31] and silencing of PTGS2 decreases IL11 expression in MDA-
MB-231 cells [32,33]. Therefore, in addition to direct targeting,
the inhibitory effects of miR-204 and -379 on IL-11 expression
might in part be an indirect consequence of reduced PTGS2
activity. In line with a previous finding by Wang et al. [16], we also
saw downregulation of TGFBR2 in response to miR-204. This is
an additional mechanism likely to contribute to the attenuated
TGF-b induction of IL11 in miR-204-transfected cells. Further-
more, miR-204 downregulated CDC42, which has been implicated
in non-Smad TGF-b signaling [34,35], and IL6, a transcriptional
target of TGF-b [36]. MiR-379, in turn, downregulated the
expression of BMP2 and a TGF-b target gene SERPINE1, both of
which have been implicated in the development of breast cancer
bone metastases [37–40].
We further delineated the TGF-b related regulatory mechan-
isms of miR-204 and -379 using a Smad reporter assay and
demonstrated that miR-379 inhibited the TGF-b-induced binding
of the Smad complex to its response element, indicating an
additional contributing mechanism for the IL11 inhibition by
miR-379. In contrast, miR-211 (as well as miR-204 but not
significantly) increased the Smad transcriptional activity. These
findings were supported by the opposing effects of specific Anti-
miR inhibitors against miR-204 and -379. TGF-b signaling
through the Smad pathway is a critical mediator of bone
metastasis and regulates the expression of several bone metasta-
sis-relevant growth factors in breast cancer cells. Blockade of
Smad-mediated TGF-b signaling by overexpression of Smad7 in
breast cancer cells has been shown to reduce bone metastases [41].
In addition, TGF-b signaling induces EMT, whereby epithelial
cancer cells acquire a mesenchymal-like phenotype with motile
and invasive characteristics. Our finding on the inhibitory effect of
miR-379 on Smad signaling is consistent with our gene expression
profiling analysis showing a highly significant correlation between
the genes downregulated by miR-379 and two previously
published gene sets: genes upregulated in basal subtype of clinical
breast cancer samples and genes downregulated in luminal-like
breast cancer cell lines as compared to the mesenchymal-like ones.
This underlines the functional relevance of the gene signature
induced by miR-379 and also suggests associations of clinical
relevance in regard to EMT and breast cancer subtypes.
In conclusion, our studies bring several novel insights into the
miRNA-driven mechanisms of bone metastasis. First, low expres-
sion of miR-200a, -200b, and -429 in highly bone metastatic
MDA-MB-231(SA) cells is in line with the previously reported
metastasis-regulating functions of these miRNAs. Second, miR-
204, -211, and -379 directly downregulate a key pathogenetic
process in breast cancer metastasis, the TGF-b-induced expression
of IL11. MiR-379 also inhibits TGF-b signaling through Smad2/
3/4 transcription factors. Finally, miR-204 and -379 downregulate
the expression of several metastasis-relevant genes, and miR-379
Figure 5. Effects of miR-204, -211, and -379 on Smad signaling. Smad signaling was quantified using a luciferase construct which encodes
the firefly luciferase reporter gene under the control of a minimal (m)CMV promoter and tandem repeats of the Smad transcriptional response
element. The luciferase reporter construct and miRNA precursors were co-transfected into MDA-MB-231(SA) cells (n=3), and the medium was
replaced with serum-free medium 16 hours after transfection. TGF-b was added 8 hours later. Activity of the firefly luciferase reporter and Renilla
luciferase was measured after 16 hour TGF-b induction. * p,0.05, ** p,0.01, as compared to the Pre-miR negative control and Smad reporter-
transfected cells.
doi:10.1371/journal.pone.0037361.g005
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cancer subtype and genes downregulated in luminal-like breast
cancer cell lines. Thus, our results suggest that these miRNAs may
be key cellular mediators of the metastatic process in breast cancer
in vitro, with potential clinical relevance.
Materials and Methods
Cell lines and Culture Conditions
The parental MDA-MB-231 cell line was obtained from the
American Type Culture Collection (ATCC). MDA-MB-231(SA)
cells were spontaneously derived from these cells during in vitro
culture and comprehensively characterized by comparative
genomic hybridization and genome-wide gene expression profiling
by us as described in [14]. Cells were maintained in low-glucose
DMEM medium with 10% inactivated fetal bovine serum (FBS),
1% nonessential amino acids, 100 U/mL penicillin and 100 mg/
mL streptomycin in an incubator with a humidified atmosphere of
95% air and 5% CO2 at 37uC.
MiRNA Expression Analysis
RNA was isolated from MDA-MB-231(SA) and parental MDA-
MB-231 cells using the mirVana miRNA Kit (Applied Biosystems).
MiRNA microarray analyses were done by Agilent Technologies
Inc. using the Agilent microarray platform v1, which contained
probes for 455 human miRNAs. The data were normalized by
variance stabilization [42].
IL-11 and Cell Viability Assays
Cells were transfected with miRNA precursors (Pre-miR,
Ambion) or miRNA inhibitors (Anti-miR, Ambion) at a final
concentration of 22 nM in 384-well plates or 20 nM in 96-well
plates. SiLentFect (Bio-Rad) was incubated with OptiMEM
medium for 10 minutes after which the mixture was added to
the wells containing the preprinted Pre-miRs or Anti-miRs. Cells
were treated with trypsin inhibitor (Sigma-Aldrich) and plated for
transfection in low-glucose DMEM medium with 1% nonessential
amino acids, 0.5% BSA, and 100 U/mL penicillin and 100 mg/
mL streptomycin. 24 hours after transfection, medium was
changed and TGF-b was added to the final concentration of
5 ng/mL. Medium samples were collected 48 hours after trans-
fection. IL-11 concentration in the conditioned medium was
measured using the DuoSet ELISA Development System for
human IL-11 (R&D Systems) according to the manufacturer’s
instructions. IL-11 concentration was normalized to the number of
viable cells in the well which was measured using the CellTiter-
Blue assay (Promega Corporation, Madison, WI, USA) according
to the manufacturer’s instructions.
Analysis of Gene Expression by Quantitative Real-time
RT-PCR
RNA isolation, reverse transcription, and TaqMan analyses
were done as previously described [14]. The primers and probes
are listed in the Table S7.
Luciferase Reporter Assays
The luciferase assays were done in 96-well plates. Binding to the
IL11 39 UTR sequence was assayed in two parts: base pairs 1–450
(1) and 451–1,618 (2), and two luciferase reporter constructs, each
containing one of these fragments. These constructs were ordered
from SwitchGear Genomics (Menlo Park, CA, USA). One of the
IL11 39 UTR luciferase reporter constructs (70 ng) along with
miRNA precursors (30 nM) and Renilla luciferase plasmid (20 ng)
as a control were co-transfected into MDA-MB-231(SA) cells using
0.5 mL Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s instructions. Luciferase levels were measured 28 hours
after transfection, using the Dual-Glo Luciferase Assay System
(Promega Corporation) according to the manufacturer’s instruc-
tions. The background signal from the untransfected cells was
subtracted, and the firefly reporter values were divided with the
respective Renilla values. Smad signaling was quantified using the
Cignal Smad Reporter Assay Kit (SABiosciences, Fredrick, MD,
USA). MiRNA precursors (20 nM) or Anti-miR inhibitors
(50 nM) along with 100 ng luciferase reporter construct were co-
transfected into the cells using 0.5 mL Lipofectamine 2000.
Medium was replaced with serum-free medium 6–16 hours after
transfection, and 5 ng/ml TGF-b was added 8–17 hours later.
Activity of the firefly luciferase reporter and Renilla luciferase was
measured after 8–16 hour TGF-b induction using the Dual-Glo
Luciferase Assay System as described above for the UTR reporter
assay. The exact time points are indicated in the figure legends.
Gene Expression Profiling
MDA-MB-231(SA) cells were transfected with miRNA pre-
cursors, IL11 siRNA (catalog number SI00013475, Qiagen), or
negative control siRNA (catalog number 1027281, Qiagen) at
a final concentration of 20 nM as described for the IL-11 assay
above and plated in low-glucose DMEM medium with 1%
nonessential amino acids, 0.5% BSA, 100 U/mL penicillin and
100 mg/mL streptomycin, and 5 ng/mL TGF-b in 6-well plates.
Total RNA was extracted from the cells 24 hours after trans-
fection. The RNA was purified using the mirVana kit according to
the manufacturer’s instructions. Purified total RNA (300 ng) was
amplified with the Illumina RNA TotalPrep Amplification kit
(Ambion) and biotinylated. The RNA/cRNA concentrations were
measured with Nanodrop ND-1000 before and after the
amplifications, and RNA/cRNA quality was controlled by
BioRad’s Experion electrophoresis station. The biotin labeled
cRNA (0.75 mg) was hybridized to Illumina Sentrix HumanHT-12
Expression BeadChips, version 3, at 58uC for 18 hours according
to the Illumina Whole-Genome Gene Expression Direct Hybrid-
ization protocol, revision A. The hybridization was detected with
1 mg/ml Cyanine3-streptavidine (GE Healthcare Limited, UK).
The arrays were scanned with Illumina BeadArray Reader,
BeadScan software version 3.5. Data analysis and visualization was
done using standard and custom algorithms implemented in the
R/BioConductor framework for statistical computing [43,44].
Raw data was transformed using the variance-stabilizing trans-
formation method described by Lin et al. [45] and implemented in
the ‘lumi’ package [46]. A linear model was fit to the data, and
differential gene expression was assessed by computing empirical
Bayes statistics as implemented in the ‘limma’ package [47]. The
data were deposited in the ArrayExpress database (http://www.
ebi.ac.uk/arrayexpress/) and are accessible under the accession
number E-TABM-1220.
MiRNA Target Prediction
MiRNA precursors were selected for the cell-based screen using
the following prediction algorithms: miRanda [48], PicTar [49],
and TargetScan version 4.0 [50]. The subsequent analyses of the
potential binding sites for miR-204, -211, and -379 in the 39 UTR
of IL11 and the genes that were downregulated in response to
miR-204 or -379 were done using the miRNA target prediction
algorithms miRanda (microRNA.org August 2010 release),
PicTar, TargetScan version 5.2, DIANA-microT version 3.0
[51,52], miRDB version 3.0 [53,54], and PITA version 6 [55].
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The results are reported as mean 6 SD. Statistical significance
of the results were analyzed using an unpaired Student’s t test.
Supporting Information
Figure S1 Effects of Anti-miR-204 and -379 on Smad
signaling in MDA-MB-231(SA) (A) and parental MDA-
MB-231 (B) cells. Smad signaling was quantified using
a luciferase construct which encodes the firefly luciferase reporter
gene under the control of a minimal (m)CMV promoter and
tandem repeats of the Smad transcriptional response element. The
luciferase reporter construct and the Anti-miR were co-transfected
into MDA-MB-231(SA) (n=4) or MDA-MB-231 cells (n=3), and
the medium was replaced with serum-free medium 6 hours after
transfection. TGF-b was added 17 hours later. Activity of the
firefly luciferase reporter and Renilla luciferase was measured after
8 hour TGF-b induction. * p,0.05, ** p,0.01, as compared to
the Anti-miR negative control and Smad reporter-transfected
cells.
(TIF)
Table S1 Expression of 455 miRNAs in highly metastatic MDA-
MB-231(SA) and parental MDA-MB-231 cells.
(XLS)
Table S2 Predicted miRNA seed sequence binding sites in the
IL11 3’ UTR. The number of mismatches and G:U wobble pairs
are given in the parentheses.
(XLS)
Table S3 Genes over 1.5-fold under- or overexpressed in
response to miR-204.
(XLS)
Table S4 Genes over 1.5-fold under- or overexpressed in
response to miR-379.
(XLS)
Table S5 Overlap between the genes over 1.5-fold down-
regulated in response to miR-204 in MDA-MB-231(SA) cells and
gene sets in the Molecular Signatures Database (MSigDB). The
most significantly overlapping gene sets are shown.
(XLS)
Table S6 Overlap between the genes over 1.5-fold down-
regulated in response to miR-379 in MDA-MB-231(SA) cells and
gene sets in the Molecular Signatures Database (MSigDB). The
most significantly overlapping gene sets are shown.
(XLS)
Table S7 Primers and probes used for quantitative RT-PCR.
(XLS)
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